AR
IRMD icon

Advisory Research’s iRadimed IRMD Stock Holding History

Advisory Research’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,232
Closed -$533K – 239
2023
Q4 		$533K Sell
11,232
-208
-2% -$8.74K 0.08% 231
2023
Q3 		$508K Sell
11,440
-7,034
-38% -$327K 0.07% 278
2023
Q2 		$882K Buy
+18,474
New +$833K 0.11% 220
2022
Q4 		– Sell
-9,498
Closed -$285K – 384
2022
Q3 		$285K Buy
+9,498
New +$331K 0.03% 282
2016
Q3 		– Sell
-25,535
Closed -$556K – 264
2016
Q2 		$556K Sell
25,535
-78,165
-75% -$1.41M 0.01% 205
2016
Q1 		$1.99M Buy
103,700
+73,700
+246% +$1.41M 0.04% 144
2015
Q4 		$841K Buy
+30,000
New +$848K 0.01% 206

Other funds holding IRMD

NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
RCMC
RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return
BCM
Bares Capital Management Austin, Texas $1.08B AUM 38.13% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Advisory Research's IRMD Position: Q1 2024 in Review

Advisory Research sold out of iRadimed (IRMD) in Q1 2024, closing a stake of 11,232 shares — an estimated $533K sold.

Advisory Research first reported a position in IRMD in Q4 2015 and held it in 7 quarters. The position peaked at $1.99M in Q1 2016. 127 funds tracked by Wall St. Rank hold IRMD as of Q1 2024.

  • Advisory Research reported no remaining iRadimed position as of Q1 2024 after selling out during the quarter.
  • Advisory Research sold 11,232 iRadimed shares in Q1 2024, an estimated $533K.
  • Advisory Research first reported a position in iRadimed in Q4 2015 and held it in 7 quarters.
  • Advisory Research's iRadimed position peaked at $1.99M in Q1 2016.
  • 127 funds tracked by Wall St. Rank held iRadimed as of Q1 2024.

Based on Advisory Research's 13F filing for Q1 2024, filed 14 May 2024.